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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
Protocol-Based Care for Early Septic Shock
To the Editor: In the Protocolized Care for Ear-
ly Septic Shock (ProCESS) study (May 1 issue),1 
the investigators report that protocol-based early 
goal-directed therapy (EGDT) did not improve 
the outcome in patients with septic shock. Since 
fluid therapy is an essential component of EGDT, 
it would be useful to know what types of fluid 
were administered. During the first 72 hours of 
care, patients received about 6.5 liters of intrave-
nous fluids, and there was a mean increase in the 
serum chloride level from 100 mmol per liter to 
between 106 and 108 mmol per liter. In a recent 
study,2 a similar increase in the serum chloride 
level from 103 to 108.5 mmol per liter 60 minutes 
after the infusion of 2 liters of 0.9% sodium chlo-
ride in healthy participants was associated with a 
40% decrease in renal blood-flow velocity (as 
measured in centimeters per second) and the 
perfusion of renal cortical tissue. Additional evi-
dence supports the adverse renal effects of hy-
perchloremia.2-5 Since such adverse effects might 
have modified the findings, and since the ad-
ministration of large amounts of hyperchloremic 
0.9% sodium chloride is the probable cause of 
the reported hyperchloremia, can the authors 
provide information on the types of fluid that 
were administered?
Hans-Joachim Priebe, M.D.
University of Freiburg 
Freiburg, Germany 
hans-joachim.priebe@uniklinik-freiburg.de
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To the Editor: In the ProCESS study, all three 
study groups had an improvement in the rate of 
death (ranging from 17 to 19 percentage points), 
as compared with values predicted by their score 
on the Acute Physiology and Chronic Health 
Evaluation (APACHE) II, which shows that proto-
colized care does work. As compared with the 
patients in the Early Goal-Directed Therapy 
study,1 the patients in the ProCESS study had a 
lower severity of illness because the initial lactate 
values were lower and the inclusion criteria in-
cluded a 1-liter fluid bolus instead of 20 to 30 ml 
per kilogram of body weight.2 The majority of 
the study sites had preexisting sepsis programs 
that were influenced by the Surviving Sepsis 
Campaign, as shown by the rate of early central-
catheter placement of 57% in the usual-care 
group, a procedure that has been associated with 
a 10% reduction in mortality.3 Even the delayed 
introduction of monitoring of central venous 
pressure and central venous oxygen saturation 
after the 6-hour avoidance period can still give 
rise to improved outcomes.4 Moreover, the high 
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likelihood that the usual-care group received pre-
existing protocol-driven care, as outlined in the 
Surviving Sepsis Campaign, could explain the 
low mortality and small between-group differ-
ences (Table 1). Does it make sense to change a 
historically successful protocol that has im-
proved patient outcomes? The recent continued 
endorsement of EGDT by the Surviving Sepsis 
Campaign supports the status quo.5
Angel Coz Yataco, M.D.
University of Kentucky 
Lexington, KY 
angel.coz@uky.edu
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ported.
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To the Editor: Although it is indeed good news 
that advances in the field have decreased short-
term sepsis-related mortality over time since the 
original report of EGDT,1,2 and that this lower 
mortality may have influenced the ProCESS trial 
results to some extent, it is important to recog-
nize that only half the patients in the ProCESS 
population were able to be discharged home 
from the hospital, and the 1-year mortality ap-
pears to be nearly double the short-term mortal-
ity. Other recent studies have found similar dis-
cordance. As highlighted in the Journal,3 chronic 
critical illness (i.e., critically illness in patients 
who neither die in the acute phase nor recover) is 
an emerging public health problem that is both 
created and sustained by advances in critical care 
medicine. How many patients in the ProCESS 
study received the diagnosis of chronic critical 
illness? And should the primary outcome in sep-
sis trials incorporate the occurrence of chronic 
critical illness as a “poor” outcome?
Stephen Trzeciak, M.D., M.P.H.
Cooper University Hospital 
Camden, NJ 
trzeciak-stephen@cooperhealth.edu
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Table 1. Differences in Mortality and Key Clinical Values in the EGDT Study and the ProCESS Study.*
Variable EGDT Study ProCESS Study
EGDT 
Group
Control
Group
EGDT
Group
Protocol-Based 
Standard-Therapy 
Group
Usual-Care 
Group
Predicted mortality on the basis of APACHE II 
score (%)
40.3 36.9 38.2 37.5 37.9
Actual mortality (%) 30.5 46.5 21.0 18.2 18.9
Lactate (mmol/liter)
At 0 hr 7.7 6.9 4.8  5.0 4.8
At 6 hr 4.3 4.9 NR NR NR
Central venous oxygen saturation (%)
At 0 hr 48.6 49.2 71.0 NA NA
At 6 hr 77.3 66.0 NR NA NA
Central-catheter rate at 6 hr (%) 100 100 93.6 56.5 57.9
* APACHE denotes Acute Physiology and Chronic Health Evaluation, NA not applicable, and NR not reported.
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To the Editor: The ProCESS trial represents a 
little-understood paradigm shift. Twenty years 
ago, when I began practicing emergency medi-
cine, the administration of antibiotics without an 
identified source of infection violated accepted 
practice. We can quibble over monitoring of cen-
tral venous pressure and lactate clearance. The 
critical change, though, is that in this “new era,” 
as described in the editorial accompanying the 
article on the ProCESS trial,1 we are urged to 
treat sepsis quickly on clinical evidence rather 
than on delayed bacteriologic evidence.
Antonio J. Dajer, M.D.
New York Presbyterian–Lower Manhattan Hospital 
New York, NY 
tonydajer@aol.com
No potential conflict of interest relevant to this letter was re-
ported.
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The authors reply: We agree with Priebe that 
saline can cause hyperchloremia and acidosis. In 
our study, we did not evaluate different fluid for-
mulations. Saline comprised 93% of intravenous 
fluids (range, 92 to 96% in the three study 
groups) during the first 6 hours and 83% (range, 
80 to 86%) from 6 hours to 72 hours, which we 
consider within the scope of usual U.S. practice.1 
We also agree with Dajer regarding the impor-
tance of the early use of antibiotics in patients 
who appear to be sick and infected, such as pa-
tients enrolled in our study, although use of these 
drugs in less sick patients may enhance antibi-
otic resistance.
Modern studies typically report outcomes 
better than those predicted by the APACHE II 
score, presumably because of the many advances 
in care since the original APACHE II calibration 
30 years ago.2 Coz Yataco notes that our cohort 
had some features that suggested a lower severity 
of illness than that in the study by Rivers et al.3 
However, in our reported subgroup analyses, the 
sickest third of patients on the basis of lactate 
levels or APACHE II scores, who were sicker than 
patients in the cohort study by Rivers et al., 
showed no benefit from EGDT. Thus, we do not 
believe that differences in severity of illness explain 
the differences in results between the two trials.
We disagree that central-catheter use in 57% 
of patients in the control group is evidence that 
sites all followed the EGDT-based resuscitation 
guidelines of the Surviving Sepsis Campaign. 
Central-catheter use is extremely common, espe-
cially for patients admitted to the intensive care 
unit. Furthermore, as we reported, only 3.5% and 
4.0% of patients in the two control groups under-
went monitoring of central venous oxygen satu-
ration,1 a prerequisite for EGDT. Coz Yataco 
suggests that the resuscitation bundle that is 
recommended by the Surviving Sepsis Campaign 
should remain intact because observational stud-
ies report good outcomes. We contend that clini-
cal guidelines should be modified as robust data 
emerge from randomized trials, and the Surviv-
ing Sepsis Campaign bundles have undergone 
numerous changes in the past on the basis of 
just such a process.4
We agree with Trzeciak that enthusiasm for 
the decline in hospital mortality from sepsis must 
be tempered by concern that many patients who 
are discharged may die in the following months, 
as we reported, or suffer protracted sequelae. 
That said, in our study, only 45 of 1341 patients 
(3.4%) were still undergoing mechanical ventila-
tion at the time of discharge. We agree that as-
sessing outcomes beyond short-term mortality 
are key considerations for future sepsis trials.
Derek C. Angus, M.D., M.P.H. 
Donald M. Yealy, M.D. 
John A. Kellum, M.D.
University of Pittsburgh 
Pittsburgh, PA 
angusdc@upmc.edu
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The editorialist replies: Dajer astutely points 
out that the one key element that the ProCESS 
trial procedures shared with those in the preced-
ing EGDT trial1 was that antimicrobials were ad-
ministered within the first 2 hours after sepsis 
was identified in circulatory failure. The practice 
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of deferring antimicrobial therapy in favor of a 
prolonged search or unassailable evidence of the 
source of the infection has been difficult to jus-
tify given studies in patients with septic shock 
that documented mortality benefits from the ad-
ministration of antimicrobials to which the patho-
genic organism was sensitive,2 better outcomes 
with combination therapy as compared with 
monotherapy therapy,3 and particularly the real-
ization that each hour that antimicrobial therapy 
is deferred has been associated with a 7.6% de-
crease in survival for patients with septic shock.4 
The training we received to identify the source of 
any serious infection is as valid today as it was 
when it was first brought to our attention; what 
has changed is the amount of time allotted for 
performing investigations before starting anti-
biotic therapy.
Craig M. Lilly, M.D.
University of Massachusetts Medical School 
Worcester, MA 
craig.lilly@umassmed.edu
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Case 9-2014: A Woman with Increasing Dyspnea
To the Editor: Saukkonen et al. (March 20 is-
sue)1 describe a 34-year-old woman with severe 
pulmonary hypertension and Raynaud’s phenom-
enon due to mixed connective-tissue disease. 
However, the authors never identified the cause 
of severe systemic hypertension (which is not 
typically seen in mixed connective-tissue disease) 
in this patient. Particularly in light of her auto-
immune disease, I wonder whether she was test-
ed for the antiphospholipid syndrome. In one of 
his early descriptions of this syndrome in 1984, 
Hughes reported labile hypertension, often with 
associated livedo reticularis, Raynaud’s phenom-
enon, or both.2 Indeed, since then, hypertension 
— often severe — has been observed in as many 
as 40 to 50% of patients with primary antiphos-
pholipid syndrome. Hypertension in this syndrome 
is most often renovascular in origin, including 
not only thrombosis or focal arterial stenosis of 
the renal artery, but also intrarenal thrombotic 
microangiopathy (antiphospholipid syndrome ne-
phropathy), and severe hypertension may be the 
initial manifestation of the antiphospholipid 
syndrome in these patients.3 Hypertension in this 
syndrome may also occur as a result of an associ-
ated autonomic disorder (e.g., hyperadrenergic 
postural tachycardia syndrome), and these pa-
tients also often have livedo reticularis, Raynaud’s 
phenomenon, or both.4
Jill R. Schofield, M.D.
University of Colorado 
Denver, CO 
jill.schofield@ucdenver.edu
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To the Editor: We would like to raise two issues 
with regard to the Case Record by Saukkonen 
et al. First, pulmonary veno-occlusive disease 
should be considered in the differential diagno-
sis of pulmonary arterial hypertension associat-
ed with connective-tissue diseases. Pulmonary 
arterial hypertension and pulmonary veno-occlu-
sive disease share predisposing conditions and 
clinical and hemodynamic features. The exclusion 
of pulmonary veno-occlusive disease is crucial, 
since patients with pulmonary veno-occlusive 
disease, besides having a worse prognosis, may 
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